News

NMT Pharma has completed due diligence of the CZ-48 drug for cancer treatment in major markets. "This is a new milestone to expand our business from drug delivery

Recipharm has acquired 74 % of the shares for a purchase consideration of INR 6,713 million (SEK 824 million)[1] on a cash and debt free basis. Thomas Eldered,

TSC is a rare genetic condition characterized by formation of non-malignant tumors in several organs. The 16-week dose-ranging trial will evaluate Epidiolex against placebo in about 200 patients.

The double-blind, two-arm parallel group study will randomize 120 patients to receive 12 mg of Bekinda or placebo once daily for eight weeks. The primary endpoint is the

Venclexta is being developed by AbbVie and Genentech. It is the first therapy approved by the FDA, targeting the the B-cell lymphoma 2 (BCL-2) protein which supports cancer

Dr. Mehdi Shahidi, Medical Head, Solid Tumour Oncology, Boehringer Ingelheim commented: "Whilst there have been some recent and significant advances in the treatment of squamous cell carcinoma of

In its report on that inspection, the Thai FDA stated that, "The facility is built according to the pre-approved floor plan and is now deemed suitable for the

IONIS-TTRRx is currently being evaluated by IONIS in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy. A Phase 3 study, CARDIO-TTR, is

This collaboration is the first to expand on Immunovaccine’s previously announced research project in which the company will apply its DepoVax™ platform to development of a Zika virus